

1 **Associations Between Female Sex Hormones and Skeletal Muscle Ageing: The**
2 **Baltimore Longitudinal Study of Ageing**

3

4 Annabel J. Critchlow^a, Sarah E. Alexander^b, Danielle Hiam^a, Luigi Ferrucci^d, David Scott^{a,c}, Séverine
5 Lamon^a

6

7 ^aSchool of Exercise and Nutrition Sciences, Institute for Physical Activity and Nutrition (IPAN),
8 Deakin University, Geelong, Australia.

9 ^bCardiometabolic Health and Exercise Physiology, Baker Heart and Diabetes Institute, Melbourne,
10 Australia

11 ^cSchool of Clinical Sciences at Monash Health, Monash University, Clayton, Australia.

12 ^dNational Institute on Aging, National Institutes of Health, Baltimore, Maryland, United States

13

14

15 **Corresponding author:**

16 A/Prof. Séverine Lamon

17 School of Exercise and Nutrition Sciences, Faculty of Health

18 Deakin University, 221 Burwood Hwy, Burwood 3125.

19 Australia

20 Ph (+61 3) 9244 5571

21 Email: severine.lamon@deakin.edu.au

22

23 **Author contact details:**

24 Annabel Critchlow: annabel.critchlow@deakin.edu.au

25 Dr Sarah Alexander: sarah.alexander@baker.edu.au

26 Dr Danielle Hiam: danielle.hiam@deakin.edu.au

27 Dr Luigi Ferruci: ferruccilu@grc.nia.nih.gov

28 A/Prof David Scott: d.scott@deakin.edu.au

29

30 Word count: 4461

31 Number of figures: 1

32 Number of tables: 2

33 Number of references: 38

34 **Abstract**

35 **Background:** To date, most research investigating the influence of circulating sex hormones on
36 ageing female skeletal muscle has been cross-sectional and focused only on dichotomised young and
37 old, or pre- versus post-menopausal groups. This excludes an important transitional period from high
38 to low circulating oestrogen. Using secondary data from the Baltimore Longitudinal Study of Aging,
39 this study aimed to investigate cross-sectional and longitudinal associations between circulating sex
40 hormones and skeletal muscle mass and function across a continuum of ages.

41 **Methods:** Multiple and binomial linear regression was used to map cross-sectional (n=319) and
42 longitudinal (n=83) associations between circulating sex hormones (oestradiol (E2), free oestradiol
43 index (FEI), free (TT) and bioavailable testosterone (BioT), testosterone/oestradiol ratio (T/E2)) and
44 skeletal muscle mass and function in healthy females. Cross-sectional models analysed females across
45 an ageing continuum (24-89 years) and longitudinal associations were tested across 4-6 years of
46 ageing in females over 50 years old. Models were adjusted for age, height, physical activity,
47 comorbidities, and ethnicity.

48 **Results:** Cross-sectionally, serum E2 and FEI were positively associated with relative appendicular
49 lean mass (ALM; $\beta=0.28$ and 0.20 , respectively, $p<0.05$) and thigh muscle percentage ($\beta=0.19$ and
50 0.15 , respectively, $p<0.05$). E2 and FEI were negatively associated with total body fat percentage ($\beta=-$
51 0.30 and -0.21 , respectively, $p<0.05$). BioT was positively associated with absolute ALM ($\beta=0.13$,
52 $p<0.05$) and total body fat percentage ($\beta=0.18$, $p<0.05$). TT was negatively associated with total body
53 fat percentage ($\beta=-0.14$, $p<0.05$). The T/E2 ratio was negatively associated with thigh muscle CSA
54 ($\beta=-0.08$, $p<0.05$) and hamstring strength ($\beta=-0.12$, $p<0.05$). Across 4-6 years, $\Delta E2$ and ΔFEI were
55 positively associated with the change in ALM ($\beta=0.29$ and 0.42 , respectively, $p<0.05$), and ΔFEI was
56 positively associated with the change in handgrip strength ($\beta=0.17$, $p<0.05$). ΔTT and $\Delta BioT$ were
57 negatively associated with the change in relative ALM ($\beta=-0.25$ for both, $p<0.05$) and relative
58 quadriceps strength ($\beta=-0.12$ and -0.27 , respectively, $p<0.05$)

59 **Conclusion:** This study demonstrates novel associations between sex hormone levels and skeletal
60 muscle in females across a wide continuum of ages. We also demonstrate that longitudinal
61 fluctuations in circulating sex hormones must be considered to gain a comprehensive understanding of
62 female muscle ageing.

63

64 **Keywords:** oestrogen, ovarian hormones, skeletal muscle, ageing

65 **Introduction**

66 The World Health Organization [1] predicts the global population above 60 years of age will double
67 from 2019 to 2050. However, improvements to increase the lifespan have not been matched by
68 advancements in the health span; that is, the length of time a person remains healthy, not just alive.
69 While females live longer than males [2], those additional years are spent in significantly poorer
70 health, highlighting a large disparity between the health span and lifespan in females compared to
71 males [3].

72 Ageing is associated with a progressive loss of muscle mass and function which presents an
73 increasingly substantial public health concern. Age-related muscle wasting is significantly associated
74 with many adverse outcomes, including reduced independence and quality of life, and increased
75 chronic disease, hospitalisation, and mortality [4]. While the prevalence of age-related muscle loss is
76 seemingly similar between the sexes [5], evidence suggests that the patterns, and therefore the
77 underlying molecular mechanisms of muscle ageing may be sex-specific. For example, females
78 undergo a rapid decline in knee extensor strength ~20 years earlier than males [6]. In addition, while
79 both sexes share the same direction of changes to the transcriptome with ageing, the magnitudes of
80 change to differentially expressed genes differs between the sexes from young and old individuals [7].

81 Testosterone and oestrogen are the predominant sex hormones in males and females, respectively.
82 While they are produced by both sexes, their profiles vary drastically across the lifespan. Females
83 undergo a dramatic decline in endogenous oestrogen production starting ~40 years of age [8],
84 meaning they can spend over a 3rd of their life in an oestrogen-deficient state. A steep reduction in
85 total and bioavailable (i.e. not bound to sex hormone-binding globulin (SHBG)) testosterone occurs in
86 the early reproductive years, which stabilises around menopause [9]. In contrast, male testosterone
87 production remains largely consistent across adult life with a gradual decline in later decades [9].
88 Oestrogen and testosterone elicit effects in multiple tissues, including skeletal muscle, by binding to
89 the oestrogen (ER) and androgen receptor (AR), respectively [10]. In females, bioavailable
90 testosterone is associated the maintenance of muscle mass [11], and oestrogen may regulate the
91 maintenance of muscle mass, strength, and mitochondrial function [12].

92 A recent systematic review by our group found a consistent reduction in muscle mass and handgrip
93 strength across the menopausal transition, however many studies show no association between
94 oestradiol concentrations (E2, the major endogenous form of oestrogen) and muscle mass or function
95 in pre- or postmenopausal females [13]. The cross-sectional nature and dichotomisation of age groups
96 in this body of evidence is a limitation because it prevents conclusions to be drawn about the effects
97 of changes in sex hormone concentrations on muscle health over time. Only one study has explored
98 this association in a longitudinal manner, reporting no relationship between baseline circulating E2 or
99 testosterone and the loss of appendicular lean mass or knee extensor strength over 3 years in

100 postmenopausal females [14]. However, it remains largely unknown how age-related fluctuations in
101 sex hormones impact the regulation of skeletal muscle across a broader age range, as associations
102 between the changes in sex hormones and skeletal muscle health across ageing and the menopausal
103 transition are still to be mapped.

104 This study used data from the Baltimore Longitudinal Study of Aging (BLSA, [15]) to address two
105 research questions. First, we aimed to determine the cross-sectional associations between circulating
106 female sex hormone concentrations and skeletal muscle mass and function across a continuum of ages
107 and hormonal status (24 to 89 years). Secondly, we aimed to investigate the longitudinal associations
108 between circulating sex hormone concentrations and the changes in muscle mass and function that
109 occurred over a 4–6-year period in females aged 50 to 87 years.

110 **Methods**

111 *Study Population*

112 This is a secondary analysis of data from the BLSA [15], an ongoing prospective study that aims to
113 extensively map the process of healthy ageing [15]. Testing is carried out at the National Institute of
114 Ageing Clinical Research Unit in Baltimore, Maryland. Healthy participants between 20-96 years
115 without any chronic disease or cognitive impairment were recruited. Data collected between 2003 and
116 2023 were utilised in this analysis. Participants under 60 years old were tested every 4 years, 60–79-
117 year-olds were tested every 2 years, and those above 80 years were tested every year.

118 *Inclusion Criteria*

119 Inclusion criteria for the present study included female BLSA participants with no missing variables
120 of interest (serum sex hormones, DXA body composition, handgrip, hamstring, and quadriceps
121 strength, and confounding variables). Data from females at their first visit was used for the cross-
122 sectional analysis if there were no missing variables (n=319). From these participants, females >50
123 years were included in the longitudinal analysis (n=83) if they had a follow up visit 4-6 years later
124 with all the required sex hormone and outcome variables. If they had multiple visits within this time
125 frame, data from the latest was used. As the BLSA recruit only healthy individuals at baseline, there
126 were no additional exclusion criteria specific to this study.

127 *Measures*

128 *Serum Hormone Analysis*

129 Fasted (12 h) blood samples were taken from participants in the morning of each visit and
130 immediately centrifuged at 4°C. Serum was aliquoted and stored at -80°C. Fasted serum hormone
131 concentrations of E2 (ng/dL) and total testosterone (TT, ng/dL) were determined by high-performance
132 liquid chromatography-tandem mass spectrometry (LC/MS; Esoterix part of LabCorp, Calabasas

133 Hills, CA). SHBG concentrations (nmol/L) were analysed via immunoradiometric assay (Esoterix part
134 of LabCorp). To determine bioavailable testosterone (BioT, ng/dL), ammonium sulphate was used to
135 separate SHBG-bound hormones from albumin-bound and free hormones (Esoterix part of LabCorp).
136 E2, TT, and BioT concentrations were converted to SI units (pmol/L, nmol/L and nmol/L,
137 respectively). The free oestrogen index (FEI) was calculated by dividing E2 (pmol/L) by SHBG
138 (nmol/L) and multiplying by 100. The testosterone to oestrogen (T/E2) ratio was calculated by
139 dividing TT (nmol/L) by E2 (pmol/L).

140 *Body Composition*

141 Body composition measures including appendicular lean mass (ALM, kg), leg lean mass (LLM, kg),
142 and total body fat mass (TBFM, kg) were assessed via whole-body DXA (Prodigy Scanner, GE,
143 Madison, WI) scans with software version 10.51.006. The scanner was calibrated daily. Reliability has
144 been assessed in 12 older (>65 years) males, showing <1% difference in fat mass (kg) between 2
145 scans, 6 weeks apart [16]. Relative ALM ($\text{kg}\cdot\text{kg}^{-1}$) was calculated by dividing appendicular lean mass
146 (kg) by total body fat mass (kg). Thigh muscle cross-sectional area (CSA, cm^2), subcutaneous fat area
147 (cm^2), intramuscular fat area (cm^2), and muscle density (HU) were assessed using computerised
148 tomography (CT) cross-sectional images of the mid-thigh (Somatom Sensation 10, Siemens, Malvern,
149 PA). Thigh muscle percentage was calculated by dividing total thigh CSA (cm^2) by muscle CSA
150 (cm^2). CT images were analysed and quantified with Geanie 2.1 software (BonAlyse Oy, Jyvaskla,
151 Finland).

152 *Muscle Function*

153 Handgrip strength (kg) was assessed using a Jamar Hydraulic hand dynamometer (Patterson Medical,
154 Warrenville, IL). Participants sat with their arm extended to 180° or shoulder height and were
155 instructed to squeeze the dynamometer as hard as possible. Maximum force was measured in three
156 trials on each hand, and the best of 6 were used in the analysis. The average of the left and right hand
157 was used in the analysis. Lower limb strength was measured using the Kin-Com isokinetic
158 dynamometer (Kin-Com model 125E version 3.2, Chattanooga Group, Chattanooga, TN) from 2003
159 to 2011, and the Biodex Multi-Joint System-Pro dynamometer (Biodex Medical System, Advantage
160 Software V4.X, Inc., Shirley, NY) from 2011 to 2023. Quadriceps strength (isokinetic knee
161 extension; Nm) and hamstring strength (isokinetic knee flexion; Nm) was measured at an angular
162 velocity of $30^\circ/\text{s}$ and $180^\circ/\text{s}$. Participants were asked to extend/flex their knee as hard as possible
163 through a range of motion set between $100\text{-}160^\circ$. They completed two practice trials, followed by
164 three test trials. The highest peak torque value was included in the analysis. Peak torque normalised to
165 leg lean mass (Nm/kg) and thigh muscle CSA (Nm/cm^2), were calculated by dividing hamstring and
166 quadriceps peak torque (Nm) by leg lean mass (kg) and thigh muscle CSA (cm^2), respectively.

167 *Physical Function*

168 Gait speed was assessed by instructing participants to walk 400 m as fast as possible after a warm-up
169 of 2.5 minutes at a usual gait speed. Chair stand ability was measured by asking participants to fold
170 their arms and stand up from a chair 10 times. The pace of the first 5 chair stands (stands/s) was
171 recorded. Participants completed three tests (6 m walk test, chair stand test, and standing balance) to
172 comprise the Short Physical Performance Battery (SPPB), a validated assessment of mobility.
173 Performance in each of the 3 tests was scored from 0 (worst) to 4 (best) and summed to give a total
174 out of 12, as previously described [17]. Finally, participants were categorised as a faller if they had at
175 least one self-reported fall in the previous 12 months.

176 *Potential confounding variables*

177 Demographic information was collected from participants via an interview, including age, ethnicity,
178 comorbidities, and total physical activity in the previous two weeks. The age adjusted Charlson
179 comorbidity index (ACCI) was determined as previously described [18]. Briefly, a score is assigned to
180 each comorbid condition, with additional points for increasing age groups.

181 *Statistical Analysis*

182 Statistical analysis was completed using Stata software version 17.0 (StataCorp, College Station, TX).
183 Data are presented as mean \pm SD and statistical significance was accepted as $p < 0.05$. Participants
184 with values that were deemed physiologically implausible (>10 SDs) were excluded. One participant
185 was excluded from the cross-sectional analysis because handgrip strength was >300 kg. Forty and 21
186 participants were excluded from the cross-sectional and longitudinal analysis, respectively, because
187 their hormone levels were below zero. Paired t-tests were performed to determine the differences
188 between variables at baseline and follow-up.

189 *Multiple regression*

190 Multiple linear regression was performed to determine the cross-sectional relationships between
191 circulating sex hormones, body composition (from DXA), and muscle function. Further outcome
192 variables were assessed in subsets of participants where measured, including thigh CT measures and
193 physical function. Additional models were performed to determine cross-sectional associations
194 between self-reported menopausal and hormonal supplementation status and all muscle outcomes. In
195 the longitudinal analysis, multiple regression models were performed to determine the relationship
196 between the change in sex hormone levels and the change in outcome measures across 4-6 years in
197 females over 50 years. Further analysis was completed to measure the longitudinal associations
198 between baseline menopausal status and HRT use and the change in muscle outcome measures.

199 Each model was adjusted for age, ethnicity, height, ACCI, and physical activity. Where significant and
200 opposing associations were detected for serum oestradiol (E2 or FEI) and testosterone (TT or BioT),

201 both hormones were added to the model to determine if they remained significantly and independently
202 associated with the outcome variable.

203 Multicollinearity was assessed by variation inflation factors with a threshold of 5. No variables
204 displayed collinearity. Normality of residuals was confirmed by plotting a histogram of studentised
205 residuals. Homoscedasticity was assessed by plotting fitted versus predicted residuals. Some
206 heteroscedasticity was observed, so robust standard errors were used. To determine the magnitude of
207 the relationships, the z-score was calculated for all independent (E2, FEI, TT, BioT, SHBG, and T/E2
208 ratio) and outcome measures (body composition, muscle function, and physical function), where zero
209 equals the mean, and 1 equals the standard deviation. Where the standardised coefficient was <0.2 , the
210 effect size of the relationship was considered ‘small’, 0.2 to 0.5 denotes a ‘medium’ effect size, and
211 >0.5 represents a ‘large’ effect size.

212 *Binomial linear regression*

213 In females over 50 years of age, binomial linear regression models were used to determine the cross-
214 sectional relationship between sex hormone levels and dichotomous physical function outcome
215 measures (mobility disability and fallers).

216 **Results**

217 *Participant characteristics*

218 Characteristics of the participants included in the cross-sectional and longitudinal analysis are shown
219 in Supplementary Tables S1 and S2, respectively. Self-reported menopausal status and hormonal
220 supplementation is shown in Table S3. In the longitudinal analysis, there was a 50.8% reduction
221 ($p<0.05$) from baseline (mean age: 64.41 ± 10.99 years) to follow up (4.86 ± 0.88 years later) in
222 circulating E2, but not in other hormones. In body composition measures, there was a 4.6% reduction
223 in thigh muscle CSA ($p<0.05$), and a 3.9% reduction in thigh muscle density ($p<0.05$). Regarding
224 muscle function, there was a reduction in absolute and relative hamstring strength at $180^\circ/s$
225 (absolute: -12%, relative to LLM: -11.2%, relative to muscle CSA: -8.4%, $p<0.05$), and absolute and
226 relative quadriceps strength at $180^\circ/s$ (absolute: -8.0%, relative to LLM: -7.5%, $p<0.05$) and $30^\circ/s$
227 (absolute: -8.2%, relative to LLM: -8.1%, relative to CSA: -4.5%, $p<0.05$). There was a 9% increase
228 in 400 m walk time ($p<0.05$).

229 *Cross-sectional analysis*

230 Adjusted cross-sectional associations between circulating sex hormones and skeletal muscle outcome
231 measures in females between 24-89 years are displayed in Table 1. Amongst the body composition
232 measures, circulating E2 and FEI were positively associated with relative ALM (kg, $p<0.05$). BioT
233 was positively associated with absolute ALM (kg, $p<0.05$) but negatively associated with relative

234 ALM (kg, $p<0.05$). E2, FEI, and TT were negatively associated with total body fat percentage
235 ($p<0.05$), but there was a positive association for BioT ($p<0.05$). E2 and FEI were positively
236 associated with thigh muscle percentage ($p<0.05$), and T/E2 ratio was negatively associated with
237 thigh muscle CSA (cm^2 , $p<0.05$). BioT was positively associated with subcutaneous and
238 intramuscular fat (kg, $p<0.05$), while E2 was negatively associated with subcutaneous fat (kg,
239 $p<0.05$). In muscle function models, T/E2 ratio was negatively associated with hamstring peak torque
240 (Nm) at $180^\circ/\text{s}$ ($p<0.05$) and BioT was positively associated with 400 m walk time (s, $p<0.05$; Table
241 1). The binomial linear regression results are displayed in Table S4. There were no significant
242 associations between any hormones and indices of mobility disability or falls in females over 50 years
243 ($n=238$).

244 Cross-sectional associations between menopausal status, hormonal supplementation and muscle
245 outcomes are displayed in Table S5. Postmenopausal status was positively associated with total body
246 fat (%), subcutaneous fat (kg, $p<0.05$), and intramuscular fat (kg, $p<0.05$), and negatively
247 associated with relative ALM (kg, $p<0.05$) and thigh muscle CSA (cm^2 , $p<0.05$). Amongst
248 postmenopausal females, use of HRT was positively associated with handgrip strength (kg, $p<0.05$).
249 In premenopausal females, use of the HCP was positively associated with relative quadriceps strength
250 normalised to leg lean mass at $30^\circ/\text{s}$ (Nm/kg, $p<0.05$). It was also negatively associated with muscle
251 density (HU, $p<0.05$), absolute and relative hamstring strength (Nm and Nm/kg, $p<0.05$), and relative
252 quadriceps strength normalised to thigh muscle CSA at $30^\circ/\text{s}$ (Nm/ cm^2 , $p<0.05$).

253 Where E2/FEI and BioT were found to have opposite associations with a muscle outcome, both
254 hormones were included in the model. BioT was added to the cross-sectional models investigating the
255 relationship between E2 and relative ALM, total body fat percentage, and subcutaneous fat, and the
256 relationship between FEI and relative ALM and total body fat. In all models, oestradiol (E2 or FEI)
257 remained significantly associated positively with relative ALM and negatively with body fat
258 percentage and subcutaneous fat, while BioT remained significantly associated in the opposite
259 direction ($p<0.05$; Table S6).

260 ***Longitudinal analysis***

261 Adjusted longitudinal associations between the change in circulating sex hormones and the change in
262 skeletal muscle outcome measures in females over 50 years are displayed in Table 2. Regarding body
263 composition, ΔE2 and ΔFEI were positively associated with the change in ALM (kg, $p<0.05$). ΔTT
264 and ΔBioT were negatively associated with the change in relative ALM (kg, $p<0.05$). ΔFEI was
265 negatively associated with the change in thigh muscle percentage ($p<0.05$), and positively associated
266 with the change in subcutaneous and intramuscular fat (kg, $p<0.05$). Regarding muscle function, ΔFEI
267 was positively associated with the change in handgrip strength (kg, $p<0.05$), but negatively associated
268 with the change in quadriceps strength (Nm) at $180^\circ/\text{s}$ ($p<0.05$). Similarly, ΔTT and ΔBioT were

269 negatively associated with the change in relative quadriceps strength at 30°/s when normalised to leg
 270 lean mass (Nm/kg, $p < 0.05$). Finally, Δ BioT was positively associated with the change in 400 m walk
 271 time (s, $p < 0.05$).

272 Longitudinal associations between baseline menopausal status, HRT use and the change in muscle
 273 outcomes across 4-6 years in females over 50 years old are displayed in Table S7. Postmenopausal
 274 status at baseline was positively associated with the change in ALM (kg, $p < 0.05$) and thigh muscle
 275 CSA (cm², $p < 0.05$). Being a current HRT user at baseline was negatively associated with the change
 276 in handgrip strength (kg, $p < 0.05$), while previous use of HRT was positively associated with the
 277 change in intramuscular fat (kg, $p < 0.05$) and relative hamstring strength normalised to muscle thigh
 278 CSA (Nm/cm², $p < 0.05$), and negatively associated with the change in thigh muscle CSA (cm²,
 279 $p < 0.05$).

280 Discussion

281 A summary of results is displayed in Figure 1. To the best of the authors knowledge, this is the first
 282 study to 1) map cross-sectional associations between sex hormones and muscle outcomes in a wide
 283 continuum of ages across the adult lifespan, and 2) investigate how changes to circulating sex
 284 hormones beyond 50 years of age associate with changes to muscle mass and function over 4-6 years.

285

Outcome Variables		E2		FEI		TT		BioT		T/E2	
		CS	L	CS	L	CS	L	CS	L	CS	L
Muscle mass	ALM		+		+			+			
	Relative ALM	+		+			-	-	-		
	Thigh muscle CSA										-
	Thigh muscle %	+		+	-						
Fat mass	Total body fat %	-		-		-		+			
	Subcutaneous fat	-			+			+			
	Intramuscular fat				+			+			
Muscle function	Handgrip strength				+						
	Hamstring strength										-
	Quadriceps strength				-						
	Relative quadriceps strength						-		-		
	400m walk time							+	+		

Figure 1. Summary of cross-sectional and longitudinal associations between serum sex hormones and body composition and muscle function. The size of the symbol corresponds to the effect size of the association: small icons denote $\beta < 0.2$, medium icons denote β between 0.2 – 0.5. Green icons show positive associations, and red icons show negative associations. ALM: appendicular lean mass; BioT: bioavailable testosterone; CS: cross-sectional; E2: oestradiol; FEI: free oestrogen index; L: longitudinal; TT: total testosterone; T/E2: ratio of total testosterone to E2.

286

287 ***Sex hormones and body composition:***

288 *Oestradiol*

289 This study highlighted a positive cross-sectional association between serum E2 levels (total and FEI)
290 and measures of muscle mass (relative ALM and thigh muscle percentage) in females across the
291 lifespan, independent of age. Additionally, both total serum E2 and FEI were negatively associated
292 with total body fat percentage and thigh subcutaneous fat, suggesting a potential role for E2 in
293 maintaining the proportion of muscle mass throughout ageing. This is line with previous mechanistic
294 work in animals highlighting an anabolic role of E2 in skeletal muscle [12]. Interestingly, this
295 contradicts with many previous cross-sectional studies investigating samples of postmenopausal
296 females, which demonstrate no associations between serum oestradiol or FEI and muscle mass [13].
297 This is likely due to the inclusion of postmenopausal females that, by definition, have very low serum
298 E2 concentrations, so there is unlikely to be large variation between participants. In contrast, the
299 current cohort spans a wide continuum of adulthood (24 to 89 years) and E2 concentrations (5 to 1872
300 pmol/L), thereby allowing us to understand how large age-related fluctuations in oestrogens impact
301 the regulation of muscle mass over the lifespan.

302 In the longitudinal analysis of females over 50 years old, the change in serum E2 and FEI across the
303 5-year follow up was positively associated with the change in absolute ALM, suggesting females with
304 a larger decline in serum E2 and FEI have a greater decline in muscle mass. This further emphasises a
305 potential role for total and free E2 in anabolic regulation, in line with the cross-sectional findings. The
306 only longitudinal study to have previously investigated this found no association between serum E2
307 and the loss of ALM over 3 years in 49 postmenopausal females [14]. However, baseline hormone
308 concentrations were used in the model, as opposed to the change in hormone concentration from
309 baseline to follow up. This suggests that it may not be baseline E2 concentration, but the magnitude of
310 change in E2 concentration from baseline, that determines the extent of muscle loss post-menopause.
311 It is therefore important to understand the temporal nature of the relationship between E2 and skeletal
312 muscle, where the population is displaying rapid changes in both hormone concentrations and muscle
313 mass and function.

314 Surprisingly, the change in serum FEI was negatively associated with the change in thigh muscle
315 percentage, and positively associated with the change in thigh subcutaneous and intramuscular fat.
316 Together this suggests that a decline in serum FEI coincides with an increased relative proportion of
317 muscle in the thigh, potentially due to declines in both subcutaneous and intramuscular fat content,
318 rather than an inverse relationship between FEI and muscle mass. We suggest this is the case, as the
319 change in FEI was positively associated with absolute ALM. Although, DXA measures of ALM do

320 not appropriately distinguish muscle from intramuscular fat, which may have exaggerated this
321 positive association, highlighting the importance of including direct measures of muscle and fat
322 infiltration from CT scans.

323 *Testosterone*

324 In the cross-sectional analysis, serum TT concentrations were negatively associated with total body fat
325 percentage and no other compositional measures. This in line with previous studies showing a lack of
326 association between serum TT and lean mass or muscle CSA in both pre- [11] and postmenopausal
327 [19-22] females, although this is the first study to investigate the association across the entire adult
328 lifespan. Instead, bioavailable (non-SHBG bound) or free (non-protein bound) forms of testosterone
329 appear to be more relevant in this context, as many studies have reported a positive association with
330 lean mass [11, 19, 20, 22-25] or muscle CSA [26-28].

331 In line with these studies, BioT concentration was positively associated with absolute ALM. However,
332 it was also positively associated with measures of fat mass (total body fat percentage, and thigh
333 subcutaneous and intramuscular fat), explaining the negative association between BioT and relative
334 ALM; an increase in fat tissue corresponds to a reduction in relative ALM, as relative ALM is indexed
335 to total body fat mass. While change in muscle and fat mass across 4-6 years of ageing may occur in
336 the same direction (i.e. both gained or lost), the resulting relative proportion of each tissue differs. A
337 similar trend was noted in the longitudinal analysis, as both the change in TT and BioT from baseline
338 to follow up were negatively associated with the change in relative ALM.

339 *Sex hormones and muscle function:*

340 *Oestradiol*

341 No significant cross-sectional associations were present between serum E2 or FEI and any measure of
342 muscle function. This contrasts with Pöllänen et al. [29] who found a positive association between
343 serum E2 and relative quadriceps femoris strength in an albeit much smaller sample (n=25) of pre-
344 and postmenopausal females. Importantly, age was not included as a confounding variable, therefore
345 these findings may just reflect the loss of both serum E2 and muscle strength with age. Indeed, when
346 age was included as a covariate, Bochud et al. [30] found no cross-sectional association between
347 urinary E2 concentrations and handgrip strength in a sample of 366 females between 18 and 90 years
348 of age.

349 The change in serum FEI was significantly and positively associated with the change in handgrip
350 strength across 4-6 years, suggesting that a greater decline in free oestradiol is related to a greater
351 decline in handgrip strength, a common proxy for overall muscle and physical function [31]. In
352 contrast, the change in serum FEI was negatively associated with the change in absolute quadriceps

353 strength. This finding is unexpected but may indicate the presence of other confounding factors that
354 are not yet identified. Rolland et al. [14] found no association between serum E2 and the loss of
355 muscle strength over 3 years in postmenopausal females, but higher serum oestrone (E1) was
356 similarly associated with a greater loss of muscle strength. E1 is an endogenous form of oestrogen
357 which becomes predominant after the menopause-related decline of serum E2 [29]. While less potent
358 than E2, its role within the muscle remains largely understudied, highlighting a target for future
359 research, particularly in postmenopausal females.

360 *Testosterone*

361 Similarly to E2, both serum TT and BioT were not cross-sectionally associated with any measures of
362 muscle strength. This is in line with other studies that investigated younger [11, 26], older [32] or both
363 pre- and postmenopausal [29] females. To our knowledge, this is the first study to investigate
364 longitudinal associations between serum testosterone and muscle function in ageing females. The
365 change in both TT and BioT levels were negatively associated with the change in relative quadriceps
366 strength, suggesting that an increase in serum testosterone concentration coincides with a decrease in
367 lower limb strength. While this is unexpected, it is further supported by the positive cross-sectional
368 and longitudinal associations between BioT and gait speed. This suggests that greater concentrations
369 of, or changes to, circulating bioavailable testosterone associate with worse physical function in the
370 lower limbs of ageing females. This is surprising as testosterone supplementation in postmenopausal
371 females can elicit anabolic effects in skeletal muscle [33], although basal molecular regulation of
372 muscle by testosterone has not yet been investigated in females.

373 *The T/E2 ratio and skeletal muscle ageing:*

374 When investigating their effects within skeletal muscle, circulating sex hormones have most often
375 been considered individually, but their production is closely linked due to common biosynthetic
376 pathways. For example, testosterone is converted to oestradiol via the enzyme aromatase; a process
377 that can be quantitatively assessed by the T/E2 ratio, where a greater T/E2 ratio indicates less
378 synthesis of E2 from testosterone, and therefore lower aromatase activity [34]. In premenopausal
379 females, the ovaries are responsible for ~95% of circulating oestradiol production, but the peripheral
380 conversion of testosterone to E2 becomes more physiologically relevant after menopause when the
381 ovaries cease E2 production [34, 35]. We observed a negative cross-sectional association between the
382 T/E2 ratio and muscle mass (thigh muscle CSA) and strength (hamstring peak torque), suggesting that
383 a lower conversion rate of testosterone to E2 is concomitant to poorer muscle quality across ageing.
384 Further research should be conducted to understand the contribution of varying oestrogen synthesis
385 pathways in the regulation of skeletal muscle throughout ageing in females.

386 ***Limitations***

387 While this study provides novel insights into the relationship between circulating sex hormones and
388 skeletal muscle ageing, it is not without limitations. Menstrual cycle phase has not been controlled
389 when scheduling premenopausal participant visits. Common measures of acute skeletal muscle
390 function are unlikely to be altered according to menstrual cycle phase [36], however, circulating E2
391 levels can vary from 70-1500 pmol/L between the early follicular and ovulatory phase [37].
392 Therefore, depending on the phase in which the blood sample was collected, the relationship between
393 circulating E2 and skeletal muscle outcomes may significantly differ. Future studies should test all
394 premenopausal participants within the early follicular phase as previously described [38], where
395 serum E2 is at its lowest or 'basal' level.

396 Secondly, premenopausal participants provided information on HCP use, but many other forms of
397 hormonal contraception are commonly used and provide external doses of oestrogen or progesterone,
398 including the intrauterine devices, implant, injections and skin patches. Therefore, a more
399 comprehensive understanding of exogenous sex hormone profiles is required to improve reliability of
400 the findings.

401 Finally, approximately one third of participants in this study were non-white, suggesting that these
402 findings are representative of a range of ethnicities. However, due to the inclusion criteria of the
403 BLSA, participants are likely healthier than the general population. Therefore, the generalisability of
404 these findings to females with multiple chronic health conditions is questionable.

405 ***Conclusion***

406 This study has demonstrated novel and divergent cross-sectional and longitudinal associations
407 between circulating sex hormones and skeletal muscle outcomes in females across the ageing
408 continuum. This emphasises the need to consider the temporal aspect of sex hormone regulation in
409 ageing female muscle, particularly across the transitional period from a high to low state of circulating
410 oestrogen. Future research should aim to identify molecular mechanisms of oestrogen action in human
411 female skeletal muscle, to determine how ageing-induced oestrogen deficiency contributes to a loss of
412 muscle mass and function in the later decades of life.

413 ***Additional Information***

414 ***Funding***

415 SL is funded by an Australian Research Council Future Fellowship (FT210100278). DS is funded by a
416 National Health and Medical Research Council (NHMRC) Australia Investigator Grant
417 (GNT1174886).

418 ***Ethical Standards***

419 Written informed consent was provided by all participants at every visit and the BSLA protocol was
420 approved by the National Institute of Health (NCT00233272). This study (project number: 2023-029)
421 has been declared exempt from ethical review on 07/02/2023 by the Deakin University Human
422 Research Ethics Committee (DUHREC) as it comprises only of secondary data analysis. Supported in
423 part by the Intramural Research Program of the National Institute on Aging, NIH. Baltimore, MD,
424 USA

425 ***Conflicts of Interest***

426 The authors declare no conflicts of interest.

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443 **References**

- 444 1. World Health Organization. Ageing and health. 2024. [https://www.who.int/news-room/fact-](https://www.who.int/news-room/fact-sheets/detail/ageing-and-health)
445 [sheets/detail/ageing-and-health](https://www.who.int/news-room/fact-sheets/detail/ageing-and-health). Accessed 22/07/2024.
- 446 2. Australian Bureau of Statistics. Twenty years of population change. 2020.
447 <https://www.abs.gov.au/articles/twenty-years-population-change>. Accessed 22/07/2024.
- 448 3. Austad SN, Fischer KE. Sex differences in lifespan. *Cell metabolism*. 2016;23:1022-33.
- 449 4. Peterson SJ, Braunschweig CA. Prevalence of Sarcopenia and Associated Outcomes in the
450 Clinical Setting. *Nutrition in Clinical Practice*. 2016;31:40-8. doi:doi.org/10.1177/0884533615622537
- 451 5. Petermann-Rocha F, Balntzi V, Gray SR, Lara J, Ho FK, Pell JP, et al. Global prevalence of
452 sarcopenia and severe sarcopenia: a systematic review and meta-analysis. *Journal of Cachexia,*
453 *Sarcopenia and Muscle*. 2022;13:86-99. doi:doi.org/10.1002/jcsm.12783
- 454 6. Haynes EMK, Neubauer NA, Cornett KMD, O'Connor BP, Jones GR, Jakobi JM. Age and
455 sex-related decline of muscle strength across the adult lifespan: a scoping review of aggregated data.
456 *Appl Physiol Nutr Metab*. 2020;45:1185-96. doi:10.1139/apnm-2020-0081
- 457 7. de Jong J, Attema BJ, van der Hoek MD, Verschuren L, Caspers MPM, Kleemann R, et al.
458 Sex differences in skeletal muscle-aging trajectory: same processes, but with a different ranking.
459 *Geroscience*. 2023;45:2367-86. doi:10.1007/s11357-023-00750-4
- 460 8. Frederiksen H, Johannsen TH, Andersen SE, Albrethsen J, Landersoe SK, Petersen JH, et al.
461 Sex-specific Estrogen Levels and Reference Intervals from Infancy to Late Adulthood Determined by
462 LC-MS/MS. *J Clin Endocrinol Metab*. 2020;105:754-68. doi:10.1210/clinem/dgz196
- 463 9. Handelsman DJ, Sikaris K, Ly LP. Estimating age-specific trends in circulating testosterone
464 and sex hormone-binding globulin in males and females across the lifespan. *Annals of Clinical*
465 *Biochemistry*. 2016;53:377-84. doi:10.1177/0004563215610589
- 466 10. Alexander SE, Pollock AC, Lamon S. The effect of sex hormones on skeletal muscle
467 adaptation in females. *European Journal of Sport Science*. 2022;22:1035-45.
468 doi:10.1080/17461391.2021.1921854

- 469 11. Alexander SE, Abbott G, Aisbett B, Wadley GD, Hnatiuk JA, Lamon S. Total testosterone is
470 not associated with lean mass or handgrip strength in pre-menopausal females. *Scientific Reports*.
471 2021;11:10226. doi:10.1038/s41598-021-89232-1
- 472 12. Pellegrino A, Tiidus PM, Vandenoort R. Mechanisms of Estrogen Influence on Skeletal
473 Muscle: Mass, Regeneration, and Mitochondrial Function. *Sports Med*. 2022;52:2853-69.
474 doi:10.1007/s40279-022-01733-9
- 475 13. Critchlow AJ, Hiam D, Williams R, Scott D, Lamon S. The role of estrogen in female skeletal
476 muscle aging: A systematic review. *Maturitas*. 2023;178:107844.
477 doi:doi.org/10.1016/j.maturitas.2023.107844
- 478 14. Rolland YM, Perry HM, 3rd, Patrick P, Banks WA, Morley JE. Loss of appendicular muscle
479 mass and loss of muscle strength in young postmenopausal women. *J Gerontol A Biol Sci Med Sci*.
480 2007;62:330-5. doi:10.1093/gerona/62.3.330
- 481 15. Shock NW. Normal human aging: The Baltimore longitudinal study of aging. Washington
482 D.C.: National Institute of Health; 1984.
- 483 16. Lindle RS, Metter EJ, Lynch NA, Fleg JL, Fozard JL, Tobin J, et al. Age and gender
484 comparisons of muscle strength in 654 women and men aged 20–93 yr. *Journal of Applied*
485 *Physiology*. 1997;83:1581-7. doi:10.1152/jappl.1997.83.5.1581
- 486 17. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short
487 physical performance battery assessing lower extremity function: association with self-reported
488 disability and prediction of mortality and nursing home admission. *J Gerontol*. 1994;49:M85-94.
489 doi:10.1093/geronj/49.2.m85
- 490 18. Zhou S, Zhang X-H, Zhang Y, Gong G, Yang X, Wan W-H. The Age-Adjusted Charlson
491 Comorbidity Index Predicts Prognosis in Elderly Cancer Patients. *Cancer Management and Research*.
492 2022;14:1683-91. doi:10.2147/CMAR.S361495
- 493 19. Gower BA, Nyman L. Associations among oral estrogen use, free testosterone concentration,
494 and lean body mass among postmenopausal women. *J Clin Endocrinol Metab*. 2000;85:4476-80.
495 doi:10.1210/jcem.85.12.7009

- 496 20. Bann D, Wu FC, Keevil B, Lashen H, Adams J, Hardy R, et al. Changes in testosterone
497 related to body composition in late midlife: Findings from the 1946 British birth cohort study. *Obesity*
498 (Silver Spring). 2015;23:1486-92. doi:10.1002/oby.21092
- 499 21. Sipilä S, Heikkinen E, Cheng S, Suominen H, Saari P, Kovanen V, et al. Endogenous
500 Hormones, Muscle Strength, and Risk of Fall-Related Fractures in Older Women. *The Journals of*
501 *Gerontology: Series A*. 2006;61:92-6. doi:10.1093/gerona/61.1.92
- 502 22. Rariy CM, Ratcliffe SJ, Weinstein R, Bhasin S, Blackman MR, Cauley JA, et al. Higher
503 serum free testosterone concentration in older women is associated with greater bone mineral density,
504 lean body mass, and total fat mass: the cardiovascular health study. *J Clin Endocrinol Metab*.
505 2011;96:989-96. doi:10.1210/jc.2010-0926
- 506 23. Hwang AC, Liu LK, Lee WJ, Chen LY, Lin MH, Peng LN, et al. Association of androgen with
507 skeletal muscle mass and muscle function among men and women aged 50 years and older in Taiwan:
508 results from the I-Lan longitudinal aging study. *Rejuvenation Res*. 2013;16:453-9.
509 doi:10.1089/rej.2013.1442
- 510 24. van Geel TA, Geusens PP, Winkens B, Sels JP, Dinant GJ. Measures of bioavailable serum
511 testosterone and estradiol and their relationships with muscle mass, muscle strength and bone mineral
512 density in postmenopausal women: a cross-sectional study. *Eur J Endocrinol*. 2009;160:681-7.
513 doi:10.1530/eje-08-0702
- 514 25. Kong SH, Kim JH, Lee JH, Hong AR, Shin CS, Cho NH. Dehydroepiandrosterone Sulfate
515 and Free Testosterone but not Estradiol are Related to Muscle Strength and Bone Microarchitecture in
516 Older Adults. *Calcif Tissue Int*. 2019;105:285-93. doi:10.1007/s00223-019-00566-5
- 517 26. Häkkinen K, Pakarinen A, Kallinen M. Neuromuscular adaptations and serum hormones in
518 women during short-term intensive strength training. *Eur J Appl Physiol Occup Physiol*. 1992;64:106-
519 11. doi:10.1007/bf00717946
- 520 27. Häkkinen K, Pakarinen A, Kraemer WJ, Häkkinen A, Valkeinen H, Alen M. Selective muscle
521 hypertrophy, changes in EMG and force, and serum hormones during strength training in older
522 women. *J Appl Physiol (1985)*. 2001;91:569-80. doi:10.1152/jappl.2001.91.2.569

- 523 28. Yee ML, Hau R, Taylor A, Guerra M, Guerra P, Darzins P, et al. Sarcopenia in women with
524 hip fracture: A comparison of hormonal biomarkers and their relationship to skeletal muscle mass and
525 function. *Osteoporos Sarcopenia*. 2020;6:139-45. doi:10.1016/j.afos.2020.06.001
- 526 29. Pöllänen E, Sipilä S, Alen M, Ronkainen PH, Ankarberg-Lindgren C, Puolakka J, et al.
527 Differential influence of peripheral and systemic sex steroids on skeletal muscle quality in pre- and
528 postmenopausal women. *Aging Cell*. 2011;10:650-60. doi:10.1111/j.1474-9726.2011.00701.x
- 529 30. Bochud M, Ponte B, Pruijm M, Ackermann D, Guessous I, Ehret G, et al. Urinary Sex Steroid
530 and Glucocorticoid Hormones Are Associated With Muscle Mass and Strength in Healthy Adults. *J*
531 *Clin Endocrinol Metab*. 2019;104:2195-215. doi:10.1210/jc.2018-01942
- 532 31. Vaishya R, Misra A, Vaish A, Ursino N, D'Ambrosi R. Hand grip strength as a proposed new
533 vital sign of health: a narrative review of evidences. *J Health Popul Nutr*. 2024;43:7.
534 doi:10.1186/s41043-024-00500-y
- 535 32. Carcaillon L, Blanco C, Alonso-Bouzón C, Alfaro-Acha A, Garcia-García FJ, Rodriguez-
536 Mañas L. Sex differences in the association between serum levels of testosterone and frailty in an
537 elderly population: the Toledo Study for Healthy Aging. *PLoS One*. 2012;7:e32401.
538 doi:10.1371/journal.pone.0032401
- 539 33. Huang G, Basaria S, Travison TG, Ho MH, Davda M, Mazer NA, et al. Testosterone dose-
540 response relationships in hysterectomized women with or without oophorectomy: effects on sexual
541 function, body composition, muscle performance and physical function in a randomized trial.
542 *Menopause*. 2014;21:612-23. doi:10.1097/gme.000000000000093
- 543 34. Cui J, Shen Y, Li R. Estrogen synthesis and signaling pathways during aging: from periphery
544 to brain. *Trends Mol Med*. 2013;19:197-209. doi:10.1016/j.molmed.2012.12.007
- 545 35. Vrtačnik P, Ostanek B, Mencej-Bedrač S, Marc J. The many faces of estrogen signaling.
546 *Biochimica medica*. 2014;24:329-42.
- 547 36. Colenso-Semple LM, D'Souza AC, Elliott-Sale KJ, Phillips SM. Current evidence shows no
548 influence of women's menstrual cycle phase on acute strength performance or adaptations to
549 resistance exercise training. *Front Sports Act Living*. 2023;5:1054542.
550 doi:10.3389/fspor.2023.1054542

551 37. Stricker R, Eberhart R, Chevailler M-C, Quinn F, Bischof P, Stricker R. Establishment of
552 detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and
553 progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT® analyzer.
554 Clinical chemistry and laboratory medicine : CCLM / FESCC. 2006;44:883-7.
555 doi:10.1515/CCLM.2006.160

556 38. Elliott-Sale KJ, Minahan CL, de Jonge X, Ackerman KE, Sipilä S, Constantini NW, et al.
557 Methodological Considerations for Studies in Sport and Exercise Science with Women as
558 Participants: A Working Guide for Standards of Practice for Research on Women. Sports Med.
559 2021;51:843-61. doi:10.1007/s40279-021-01435-8

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

Table 1. Adjusted cross-sectional associations between serum sex hormones and muscle outcomes.

Outcome variable	n	E2			FEI			TT			BioT			T/E Ratio			
		β	R^2	P	β	R^2	P	β	R^2	P	β	R^2	P	β	R^2	P	
Body composition	ALM (kg)	319	-0.02	0.32	0.72	0.07	0.33	0.13	-0.01	0.32	0.84	0.13	0.34	0.03	-0.06	0.33	0.18
	Relative appendicular lean mass (kg/kg total fat)	319	0.28	0.17	<0.01	0.20	0.14	0.02	0.11	0.12	0.06	-0.17	0.14	0.01	0.07	0.11	0.43
	Total body fat (%)	319	-0.30	0.15	<0.01	-0.21	0.11	<0.01	-0.14	0.10	<0.01	0.18	0.11	<0.01	-0.10	0.09	0.15
	Thigh muscle CSA (cm ²)	239	-0.08	0.41	0.15	0.01	0.41	0.89	-0.03	0.41	0.59	0.13	0.42	0.06	-0.08	0.41	0.04
	Thigh muscle (%)	239	0.19	0.23	<0.01	0.15	0.21	0.03	0.06	0.20	0.36	-0.10	0.20	0.12	0.01	0.20	0.86
	Muscle density (HU)	239	-0.02	0.26	0.67	-0.06	0.26	0.33	-0.02	0.26	0.81	-0.11	0.27	0.11	0.01	0.26	0.84
	Subcutaneous fat (cm ²)	239	-0.23	0.14	<0.01	-0.14	0.11	0.14	-0.05	0.09	0.38	0.19	0.12	0.01	-0.07	0.10	0.21
	Intramuscular fat (cm ²)	239	-0.07	0.05	0.33	0.02	0.04	0.80	0.00	0.04	0.96	0.28	0.11	<0.01	-0.11	0.05	0.08
Muscle Function	Handgrip strength (kg)	319	0.02	0.42	0.80	0.04	0.43	0.41	0.02	0.42	0.69	0.05	0.43	0.30	-0.04	0.43	0.17
	Hamstring peak torque (Nm)																
	180d/s	319	-0.03	0.33	0.55	0.05	0.33	0.41	-0.02	0.33	0.63	0.03	0.33	0.58	-0.12	0.34	0.02
	30d/s	319	0.02	0.35	0.74	0.09	0.36	0.07	-0.02	0.35	0.64	0.03	0.35	0.55	-0.05	0.36	0.17
	Hamstring relative peak torque (Nm/kg LLM)																
	180d/s	319	-0.04	0.14	0.53	-0.02	0.14	0.73	-0.01	0.14	0.77	-0.03	0.14	0.50	-0.10	0.14	0.06
	30d/s	319	0.01	0.17	0.85	0.03	0.17	0.56	-0.02	0.17	0.65	-0.02	0.17	0.67	-0.03	0.17	0.06
	Hamstring relative peak torque (Nm/cm ²)																
	180d/s	319	0.06	0.10	0.33	0.02	0.10	0.77	0.00	0.10	0.98	-0.11	0.11	0.09	-0.08	0.11	0.06
	30d/s	319	0.06	0.10	0.28	0.05	0.10	0.48	0.02	0.10	0.73	-0.11	0.11	0.10	0.03	0.10	0.06
	Quadriceps peak torque (Nm)																
	180d/s	319	-0.06	0.45	0.25	-0.02	0.45	0.67	0.00	0.45	0.90	0.05	0.45	0.26	0.04	0.45	0.06
	30d/s	319	-0.03	-0.37	0.48	0.05	0.37	0.37	-0.02	0.37	0.69	0.05	0.37	0.35	0.03	0.37	0.06
	Quadriceps relative peak torque (Nm/kg LLM)																
	180d/s	319	-0.07	0.32	0.22	-0.08	0.32	0.10	0.01	0.32	0.88	0.01	0.32	0.90	0.07	0.32	0.06
	30d/s	319	-0.04	0.23	0.44	-0.02	0.22	0.78	-0.03	0.22	0.55	-0.01	0.22	0.86	0.07	0.23	0.17
Quadriceps relative peak torque (Nm/cm ²)																	
180d/s	239	-0.02	0.25	0.76	-0.05	0.25	0.42	0.03	0.25	0.61	-0.08	0.25	0.30	0.04	0.25	0.54	
30d/s	239	-0.03	0.16	0.72	-0.01	0.16	0.89	0.03	0.16	0.54	-0.08	0.17	0.26	0.11	0.17	0.11	
Physical Function	400m walk time (s)	163	-0.01	0.29	0.94	0.08	0.30	0.63	0.02	0.30	0.66	0.11	0.31	0.04	0.06	0.30	0.62
	5 chair stand time (s)	203	0.30	0.08	0.11	0.19	0.08	0.32	-0.03	0.07	0.60	0.04	0.07	0.56	-0.06	0.07	0.43

Multiple regression models were adjusted for age, ethnicity, height, ACCI, and total physical activity levels in the past two weeks. Physical function measures were only assessed in females ≥ 50 years old. ALM: appendicular lean mass; BioT: bioavailable testosterone; CSA: cross-sectional area; E2: oestradiol; FEI: free oestradiol index; HU: Hounsfield unit; LLM: leg lean mass; SHBG: sex hormone-binding globulin; TT: total testosterone; T/E2: ratio of total testosterone to oestradiol.

Table 2. Adjusted longitudinal associations between serum sex hormones and muscle outcomes across 4-6 years in females ≥ 50 years old.

Outcome variable	n	$\Delta E2$			ΔFEI			ΔTT			$\Delta BioT$			$\Delta T/E$ Ratio			
		β	R^2	P	β	R^2	P	β	R^2	P	β	R^2	P	β	R^2	P	
Body composition	Δ ALM (kg)	83	0.29	0.17	0.03	0.42	0.26	<0.01	-0.12	0.11	0.09	-0.14	0.11	0.28	-0.20	0.11	0.19
	Δ Relative appendicular lean mass (kg/kg total fat)	83	0.08	0.08	0.30	0.08	0.08	0.21	-0.25	0.15	<0.01	-0.25	0.13	<0.01	0.07	0.07	0.77
	Δ Total body fat (%)	83	-0.04	0.08	0.61	-0.06	0.08	0.41	0.10	0.09	0.11	0.16	0.10	0.07	-0.12	0.09	0.62
	Δ Thigh muscle CSA (cm ²)	61	0.06	0.13	0.65	0.04	0.12	0.72	0.13	0.15	0.10	0.13	0.14	0.15	0.03	0.12	0.88
	Δ Thigh muscle (%)	61	-0.10	0.06	0.27	-0.19	0.08	0.03	-0.03	0.05	0.58	-0.01	0.05	0.94	0.04	0.05	0.87
	Δ Muscle density (HU)	61	-0.03	0.06	0.79	-0.03	0.06	0.69	-0.04	0.06	0.42	0.02	0.06	0.83	0.10	0.06	0.59
	Δ Subcutaneous fat (cm ²)	61	0.17	0.14	0.12	0.28	0.17	0.01	0.08	0.12	0.08	0.05	0.12	0.73	-0.20	0.13	0.49
	Δ Intramuscular fat (cm ²)	60	0.19	0.10	0.20	0.28	0.17	0.03	-0.02	0.06	0.69	-0.02	0.06	0.83	-0.08	0.06	0.71
Muscle Function	Δ Handgrip strength (kg)	83	0.08	0.02	0.35	0.17	0.04	<0.01	0.02	0.01	0.83	0.04	0.01	0.70	-0.09	0.02	0.56
	Δ Hamstring peak torque (Nm)																
	180d/s	83	0.09	0.07	0.48	0.07	0.07	0.69	0.01	0.06	0.92	-0.04	0.07	0.77	-0.02	0.06	0.91
	30d/s	83	0.06	0.05	0.58	0.17	0.07	0.15	-0.06	0.05	0.32	-0.18	0.07	0.13	-0.16	0.06	0.45
	Δ Hamstring relative peak torque (Nm/kg LLM)																
	180d/s	83	-0.02	0.12	0.91	-0.23	0.16	0.09	0.03	0.12	0.71	0.07	0.12	0.53	0.05	0.12	0.74
	30d/s	83	0.05	0.03	0.66	-0.04	0.03	0.71	-0.01	0.02	0.93	-0.02	0.02	0.88	0.00	0.02	0.98
	Δ Hamstring relative peak torque (Nm/cm ²)																
	180d/s		-0.04	0.11	0.75	-0.12	0.12	0.47	0.02	0.10	0.80	0.00	0.10	0.97	0.07	0.11	0.71
	30d/s		-0.02	0.05	0.83	0.01	0.05	0.90	-0.02	0.05	0.71	-0.12	0.06	0.22	-0.09	0.05	0.68
	Δ Quadriceps peak torque (Nm)	83															
	180d/s	83	-0.11	0.15	0.32	-0.31	0.22	<0.01	0.04	0.14	0.61	0.07	0.14	0.54	0.13	0.14	0.43
	30d/s		-0.07	0.04	0.60	-0.18	0.06	0.15	0.00	0.03	0.97	-0.01	0.03	0.96	0.09	0.04	0.63
	Δ Quadriceps relative peak torque (Nm/kg LLM)																
	180d/s	83	0.09	0.06	0.43	0.14	0.07	0.19	0.08	0.06	0.13	0.01	0.05	0.96	-0.08	0.05	0.75
	30d/s	83	0.02	0.07	0.84	0.16	0.10	0.22	-0.12	0.09	0.02	-0.27	0.12	0.04	-0.11	0.08	0.71
Δ Quadriceps relative peak torque (Nm/cm ²)																	
180d/s	83	-0.01	0.13	0.97	-0.17	0.16	0.28	0.04	0.14	0.49	0.07	0.14	0.54	-0.03	0.13	0.87	
30d/s	83	-0.03	0.05	0.78	-0.05	0.06	0.63	-0.06	0.06	0.32	-0.09	0.06	0.36	0.04	0.05	0.86	
Physical Function	Δ 400m walk time (s)	50	-0.01	0.47	0.92	-0.07	0.48	0.36	0.14	0.50	0.08	0.23	0.51	0.03	0.10	0.48	0.43
	Δ 5 chair stand time (s)	74	-0.02	0.06	0.81	0.00	0.06	0.95	-0.06	0.06	0.52	-0.05	0.06	0.75	-0.07	0.06	0.69

Multiple regression models were adjusted for age, ethnicity, height, ACCI, and total physical activity levels in the past two weeks. ALM: appendicular lean mass; BioT: bioavailable testosterone; CSA: cross-sectional area; E2: oestradiol; FEI: free oestradiol index; HU: Hounsfield unit; LLM: leg lean mass; SHBG: sex hormone-binding globulin; TT: total testosterone; T/E2: ratio of total testosterone to oestradiol.